This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Abstract Background/Aims: Osteosarcoma (OS) is the most common primary bone malignancy in children and young adults. Molecular mechanisms underlying the pathogenesis of OS remain to be fully understood. Several members of the E-F hand calcium-binding S100 protein family are differentially expressed in human cancers. We previously showed that S100A6 is highly expressed in OS tumors. In this study, we investigated the role of S100A4 in regulating OS proliferation and osteogenic differentiation. Methods/Results: Endogenous S100 expression was examined by semi-quantitative PCR in human OS lines. Adenoviral vector-mediated overexpression and RNAi knockdown of S100A4 were used to assess S100A4's effects on cell proliferation, migration and invasion and osteogenic differentiation. Apoptosis was assessed by using anti-caspase-3 immunostaining and flow cytometry with annexin V staining. Early osteogenic marker alkaline phosphatase (ALP) and late markers osteocalcin (OCN) and osteopontin (OPN) were assessed to determine the status of osteogenic differentiation. We found that S100A4 was elevated in metastatic MG63.2 cells. S100A4 knockdown inhibited cell proliferation, prolonged cell doubling time, and induced significant apoptosis. Silencing S100A4 expression in OS cells delayed cell wounding closure and diminished the numbers of migrated OS cells in transwell invasion assay. Furthermore, silencing S100A4 expression stimulated ALP
Introduction
Osteosarcoma (OS) is the most common primary bone malignancy, characterized by resistance to chemotherapy and frequent relapses leading to poor overall prognosis [1] [2] [3] [4] [5] [6] . Even with improved therapeutic interventions, many patients fail to achieve longterm disease free survival [5, 7] . This is in part secondary to the cytogenic modifications acquired by OS to develop resistance to chemotherapy [8] . Such cellular changes occur in many signaling pathways associated with tumor suppressor genes and oncogenes, such as p53 and Rb [2, 4, [9] [10] [11] . While the degree to which these alterations are associated with OS has yet to be established, certain genetic alterations, such as hereditary retinoblastoma or Paget's disease of bone, increase the risk of developing OS [12, 13] . Thus, there is a critical need not only to delineate the molecular underpinning of human osteosarcoma, but also to identify molecular targets for effective therapeutic interventions. S100 protein family includes more than 20 small proteins that contain E-F hand calcium-binding motifs, and is mostly located on chromosome 1q21 [14] [15] [16] , a chromosomal region with high frequencies of genetic alterations and rearrangements in human OS cells [2, 4, [9] [10] [11] . We recently found that S100A6 is highly expressed in OS tumors although its exact role in OS development remains to be fully elucidated [17, 18] . Several of S100 proteins are up-regulated or differentially expressed in human tumors and exhibit tumor-promoting activities [14, [19] [20] [21] . While elevated S100A4 expression level has been reported in several types of human cancers and exhibit metastasis-promoting activities [19, [22] [23] [24] [25] [26] , detailed mechanisms underlying S100A4's role in regulating proliferation and metastasis of tumor cells remain to be fully elucidated. Thus, a further investigation into the role of S100A4 in OS is warranted.
Using our previously characterized metastatic OS line MG63.2 [27, 28] and the commonly-used aggressive OS line 143B [29] , we investigate the role of S100A4 in regulating the proliferation, survival, and differentiation of OS cells. Our results indicate that S100A4 expression is significantly elevated in the metastatic MG63.2 cells. S100A4 knockdown inhibits cell proliferation, prolongs cell doubling time, and induces significant apoptosis. Silencing S100A4 expression in OS cells delays cell wounding closure and diminishes the numbers of migrated OS cells in transwell invasion assay. Furthermore, silencing S100A4 expression stimulates ALP activity, as well as the expression of late markers OPN and OCN, in both OS cells and mesenchymal stem cells. Thus, our results strongly suggest that S100A4 may promote OS tumor growth by regulating the cell cycle, reducing apoptosis, and inhibiting osteogenic differentiation. It is conceivable that S100A4 may serve as a marker for tumorigenic potential, as well as a therapeutic target for OS treatment.
Materials and Methods
Tissue culture Human OS cell lines MG63 and 143B, and mouse mesenchymal stem cell line C3H10T1/2 were purchased from ATCC (Manassas, VA). We also used a highly tumorigenic and metastatic MG63.2 line as previously described [27, 28] . These cells were maintained in conditions as described [30] [31] [32] . Unless otherwise indicated, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Results

Elevated S100A4 expression in the metastatic MG63.2 OS line
Several members of the S100 family play important roles in regulating tumorigenesis [14] [15] [16] . To test if S100 proteins play any role in OS growth and progression, we first detected the endogenous expression of S100A2, S100A4, S100A6, S100A7 and S100B in human OS line MG63 and its metastatic subline MG63.2 using semi-quantitative RT-PCR analysis. The Endogenous expression of S100A4 is elevated in metastatic OS cells. (A) Expression of five S100 genes in the highly metastatic MG63.2 and less metastatic MG63 cells. Total RNA was isolated from the OS lines and subjected to sqPCR analysis using primers for the specific S100 transcripts. The cDNA samples were normalized with GADPH expression level. (B) Generation of recombinant adenovirus overexpressing S100A4 or silencing S100A4 (siS100A4). Subconfluent 143B cells were infected with the same titer (MOI=5) of AdRFP, AdR-S100A4, or AdR-siS100A4. Fluorescence signal was recorded at 48h post infection (a). The adenovirus-mediated overexpression or knockdown of S100A4 was confirmed by sqPCR analysis (b) and Western blotting (c) in adenovirus-transduced 143B cells.
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MG63.2 line is a highly metastatic cell line established from its less metastatic parental MG63 line through serial passage in nude mice [27] [28] [29] . Except for S100A7, four of the examined S100 genes were expressed in MG63 and/or MG63.2 lines (Fig. 1A) . However, only S100A4 expression was significantly elevated in MG63.2 cells when compared to that in MG63 cells, suggesting that high expression of S100A4 may be associated with OS tumor progression and metastasis. Consistent with our previous reports [17, 18] , S100A6 expression was readily detected in OS cells.
Silencing S100A4 expression inhibits human OS cell proliferation
To further examine the functional role of S100A4 in OS tumorigenesis, we generated recombinant adenoviruses that express S100A4 (e.g., Ad-S100A4) and siRNA to knockdown human S100A4 expression (e.g., AdR-siS100A4), both of which co-express GFP or RFP as a marker to monitor infection efficiency and subsequent transgene expression. The adenoviral vectors were shown to transduce MG63.2 cells with high efficiency (Fig. 1B, panel a) . The adenovirus-mediated overexpression of S100A4 or knockdown of S100A4 expression was further confirmed in adenoviral transduced 143B cells using sqPCR analysis (Fig. 1B, panel  b) or Western blotting (Fig. 1B, panel c) .
We next assessed the effect of exogenous S100A4 expression or silencing S100A4 expression on OS cell proliferation in 143B cell line, which is also a commonly-used and aggressive human OS line. S100A4 overexpression increased the proliferation rate of 143B cells, with an increase in the number of cells over that of the RFP control starting day 3 (p <0.03), while silencing S100A4 expression significantly inhibited the proliferation rate of 143B cells (p<0.001) ( Fig. 2A) . A similar increase in proliferation, although to a lesser extent, was seen when S100A4 was overexpressed in MG63.2 cells (p<0.05) (Fig. 2B) . However, S100A4 knockdown resulted a pronounced decrease in proliferation rate of MG63.2 cells (p<0.001) (Fig. 2B) . The calculated doubling time (in hours) for S100A4, RFP, strong positive staining of the cleaved caspase-3 (Fig. 3B, panels a & b) . The average of cleaved caspase-3 positive cells was significantly higher in S100A4 knockdown cells (p<0.001) (Fig.  3B, panel c) . Taken together, these results suggest that S100A4 may support the survival of OS cells and that knockdown of S100A4 expression could predispose OS cells to apoptosis.
S100A4 promotes OS cell migration and invasion
The ability of tumor cells to migrate and invade is an important indicator of cell aggressiveness and metastatic potential. We assessed the effect of S100A4 on OS cell migration and transwell invasion as described [27] [28] [29] . Briefly, an artificial scratch was made in a confluent monolayer of adenoviral vector-transduced OS cells. The ability of the cells to close the gap was measured qualitatively and quantitatively in 143B cells (Fig 4A, panels a &  b) . Knockdown of S100A4 expression significantly inhibited the migration of 143B cells ( Fig  4A, panel a) . When the gap closure was quantified, the S100A4, siS100A4, and RFP groups resulted in 99%, 49%, and 86% closure, respectively (p<0.001) (Fig 4A, panel b) . Similar results were obtained for MG63.2 cells (Fig 4A, panels c & d) . Overexpression of S100A4 promoted cell migration while inhibition of S100A4 significantly inhibited migration (Fig 4A, panel c) . Quantitative gap closure for the S100A4 siS100A4, and RFP groups was approximately 94%, 63%, and 87%, respectively (p<0.05) (Fig 4A, panels c & d) .
The invasiveness of OS cells was also assessed using a previously described transwell invasion assay [27] [28] [29] . Subconfluent 143B cells were infected with Ad-S100A4, AdsiS100A4, or Ad-RFP and plated in the upper chamber of matrigel-coated transwells for 72h. We found that S100A4 overexpression led to a significantly more migrated cells than that of the RFP control group, while silencing S100A4 expression in OS cells yielded the least invading cells among the three groups (Fig. 4B, panel a) . When the numbers of migrated cells were quantified, we found that knockdown of S100A4 significantly inhibited cell invasion (p < 0.001), while overexpression of S100A4 resulted in significantly greater cell invasion compared to the RFP control (p<0.05) (Fig. 4B, panel b) . Similar results were obtained for MG63.2 cells in the transwell migration assay (data not shown). Taken together, these results strongly suggest that S100A4 may play an important role in regulating OS cell migration and invasiveness.
Knockdown of S100A4 induces osteogenic differentiation
We and others have demonstrated that osteosarcoma development may be in part caused by differentiation defects, in which mesenchymal stem cells (MSCs) fail to undergo terminal osteogenic differentiation [2, 4, 31, 53 ]. Thus, we tested the effects of S100A4 overexpression and knockdown on osteogenic differentiation of OS cells and mesenchymal stem cells (MSCs). When MG63.2 OS cells were transduced with Ad-RFP, Ad-S100A4 and AdsiS100A4 and early osteogenic marker alkaline phosphatase (ALP) activity was measured at days 3 and 5, we found that knockdown of S100A4 significantly increased ALP activity when compared with RFP control group (p< 0.001) (Fig. 5A) . We further transduced the MSC line C3H10T1/2 cells with Ad-RFP, Ad-S100A4, and AdR-siS100A4, and found that S100A4 knockdown induced a significant increase in ALP activity at day 7 (Fig. 5B) . In both OS and MSC cells, S100A4 overexpression did not induce any significant changes in ALP activity when compared with that of the RFP control (Fig. 5B) . Lastly, we examined the effects of S100A4 expression on the late osteogenic markers osteopontin (OPN) and osteocalcin (OCN). Consistent with the results obtained in ALP assays, knockdown of S100A4 expression in MG63.2 cells resulted in a significant increase in the expression of OPN (Fig. 5C, panel  a) and OCN (Fig. 5C, panel b) , while S100A4 overexpression and RFP expression resulted in minimal staining. Similar results were obtained in 143B and C3H10T1/2 cells (data not shown). These results suggest that S100A4 may play an important role in regulating the intricate balance between proliferation and differentiation of osteoblast progenitors and its pro-tumorigenic effects may be a result of shifting this intrinsic cellular balance towards cell proliferation during osteosarcoma development and progression.
Discussion
The S100 protein family has been identified as a critical part of tumorigenesis in a variety of tissues [15, 21, 54, 55 ]. Here we demonstrate that S100A4 expression is elevated in the highly metastatic MG63.2 cells when compared to the less MG63 parental line. We have shown that S100A4 overexpression promotes cell proliferation, cell migration and cell invasion, which may be in part mediated by S100A4's ability to regulate cell cycle and provide pro-survival and anti-apoptotic phenotypes in OS cells. Knockdown of S100A4 expression in OS cells enhances the expression of apoptotic marker, the cleaved caspase-3. Furthermore, we have shown that knockdown of S100A4 expression leads to an increase in both early and late osteogenic markers in OS cells as well as in MSCs, suggesting that S100A4 may play an important role in regulating the intricate balance between proliferation and differentiation of osteoblast progenitors and possibly OS cells. S100A4 plays a crucial role in the metastatic conversion of various human cancers [22] . S100A4 binds to calcium as a dimer, which induces a conformational change and enables binding to its target proteins [55] . S100 proteins have been shown to modulate cell proliferation by targeting proteins critical to cell cycle regulation [54, 56, 57] . Our results indicate that S100A4 overexpression not only induces cell proliferation, but also has an inhibitory effect on apoptotic cascade. A possible explanation may lie in the ability of S100A4 to bind p53, a regulator of the cell cycle, DNA repair, and apoptosis. S100A4 binds p53 in a calcium dependent manner through dimerization and promotes p53 degradation [57] [58] [59] . Furthermore, S100A4 can interfere with the phosphorylation of p53, preventing cells from undergoing apoptosis [23, 57, 58] . Conversely, the decreased survival observed in OS cells with S100A4 knockdown may be due to the effect of S100A4 on apoptosis. Multiple cytogenetic abnormalities have been described in OS, including mutations in p53 and Rb, and activations of oncogenes such as Myc [2, 9, 11] . Thus, the ability of S100A4 to bind and modulate the pathways associated with p53, Rb, and/or other oncogenes may explain the decrease in tumorigenic conversion upon S100A4 knockdown in OS cells.
The ability of primary tumor cells to metastasize and grow at sites distant from the primary tumor requires phenotypic conversion, including the ability to invade through basement membrane and migrate through the extracellular matrix. Invasion and migration often necessitate the primary tumor cells to increase motility and express proteins necessary for basement membrane invasion, such as matrix metalloproteinases (MMPs). Along these lines, we find that S100A4 increases the migratory and invasive abilities of OS cells. It has been reported that S100A4 interacts with non-muscle myosin II and promotes disassembly of fibers, thereby increasing the motility of cells [26, [60] [61] [62] . Furthermore, S100A4 has been shown to increase the expression of MMPs in certain cancers [26, [60] [61] [62] . Thus, it is likely that S100A4 may lead to increased tumor migration, invasion and metastasis in OS cells by regulating these proteins.
Osteogenic differentiation requires a delicate balance between proliferation and differentiation of MSCs [63] [64] [65] [66] . We have demonstrated that disruptions in this balance lead to a malignant transformation [4, 53, 67] . It is conceivable that augmentation of proliferation or inhibition of differentiation would promote tumorigenic transformation seen in OS. It has been reported that MDM2-p53 pathway regulates osteogenic differentiation [68] . The role of S100A4 in osteogenic differentiation may at least in part explain the pro-survival phenotype in OS cells. We find that S100A4 knockdown in mesenchymal stem cells promotes differentiation and decreased cellular proliferation. Furthermore, we have shown that S100A4 knockdown in human OS cells promotes the expression of osteopontin and osteocalcin, both of which are markers of terminal osteoblast differentiation. It is possible that S100A4 exhibits a pro-tumorigenic phenotype by preventing terminal osteoblastic differentiation, inhibiting apoptosis, and promoting cell proliferation.
In summary, our results suggest that S100A4 may be an important regulator in the tumorigenesis associated with OS. It is conceivable that S100A4 may be further explored as a potential marker for OS tumorigenic potential, as well as a therapeutic target.
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